Update (4:11 p.m.): Updated with Monday market close information.
The studies now indicate that with a median follow-up of 42.5 months for chronic-phase CML patients in the Phase 1 trial, Iclusig shows anti-leukemic activity in patients with limited treatment options.
The stock closed up 7.43%, or 48 cents, to $6.94. Ariad had a range of $6.74 to $7.50 for the day and holds a 52-week range of $2.15 to $23. More than 26 million shares changed hands, more than double the average volume of 10,324,300.Must Read: Warren Buffett's 25 Favorite Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts